KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Net Income towards Common Stockholders: 2009-2025

Historic Net Income towards Common Stockholders for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Sep 2025 value amounting to $71.8 million.

  • Acadia Pharmaceuticals' Net Income towards Common Stockholders rose 119.07% to $71.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $261.2 million, marking a year-over-year increase of 103.24%. This contributed to the annual value of $226.5 million for FY2024, which is 469.50% up from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Net Income towards Common Stockholders stood at $71.8 million for Q3 2025, which was up 169.18% from $26.7 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' 5-year Net Income towards Common Stockholders high stood at $143.7 million for Q4 2024, and its period low was -$113.1 million during Q1 2022.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was $26.7 million (2025), whereas its average is $25.7 million.
  • Per our database at Business Quant, Acadia Pharmaceuticals' Net Income towards Common Stockholders tumbled by 139.49% in 2023 and then surged by 2,897.22% in 2024.
  • Acadia Pharmaceuticals' Net Income towards Common Stockholders (Quarterly) stood at -$43.1 million in 2021, then increased by 3.29% to -$41.7 million in 2022, then skyrocketed by 209.89% to $45.8 million in 2023, then surged by 213.87% to $143.7 million in 2024, then spiked by 119.07% to $71.8 million in 2025.
  • Its Net Income towards Common Stockholders stands at $71.8 million for Q3 2025, versus $26.7 million for Q2 2025 and $19.0 million for Q1 2025.